Monopar Therapeutics Inc. (MNPR) |
|
2.8999 0.153 (5.56%)
|
03-24 14:53 |
|
Open: |
2.98 |
Pre. Close: |
2.7472 |
|
High:
|
2.99 |
Low:
|
2.81 |
|
Volume:
|
13,039 |
Market Cap:
|
37(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:01 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 3.7  One year: 4.29 |
| Support: |
Support1: 2.35 Support2: 1.96 |
| Resistance: |
Resistance1: 3.17 Resistance2: 3.68 |
| Pivot: |
2.8  |
| Moving Average: |
MA(5): 2.76 MA(20): 2.84
MA(100): 2.91 MA(250): 2.39 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 57.6 %D(3): 50.6 |
| RSI: |
RSI(14): 48.6 |
| 52-week: |
High: 4.88 Low: 1.39 |
| Average Vol(K): |
3-Month: 23 (K) 10-Days: 9 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNPR ] has closed below upper band by 33.2%. Bollinger Bands are 50.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.99 - 3.01 |
3.01 - 3.02 |
|
Low:
|
2.78 - 2.79 |
2.79 - 2.81 |
|
Close:
|
2.88 - 2.9 |
2.9 - 2.92 |
|
Company Description |
|
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. |
Headline News |
Thu, 23 Mar 2023
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 ... - GlobeNewswire
Tue, 21 Mar 2023
Pre-market Movers: GDEV, FRC, YELL, AG, AMBI… - Nasdaq
Mon, 20 Mar 2023
Soho House & Co Inc Says On March 17, Filed An Amendment To ... - Kalkine Media
Mon, 20 Mar 2023
Golub Capital Bdc Enters Into An Amended And Restated Senior ... - Kalkine Media
Thu, 02 Mar 2023
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and ... - InvestorPlace
Tue, 28 Feb 2023
iHeartMedia Inc reports results for the quarter ended in December ... - Kalkine Media
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
13 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
63.5 (%) |
|
% Held by Institutions
|
1.5 (%) |
|
Shares Short
|
50 (K) |
|
Shares Short P.Month
|
7 (K) |
Stock Financials |
|
EPS
|
-0.71 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.69 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-34.9 |
|
Return on Equity (ttm)
|
-61 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-8 (M) |
|
Levered Free Cash Flow
|
-4 (M) |
Stock Valuations |
|
PE Ratio
|
-4.14 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.71 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-4.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
